[PDF][PDF] Dexamethasone for COVID-19? Not so fast
TC Theoharides, P Conti - J Biol Regul Homeost Agents, 2020 - researchgate.net
Recent announcements indicated, without sharing any distinct published set of results, that
use of the corticosteroid dexamethasone in a large trial in the UK apparently reduced …
use of the corticosteroid dexamethasone in a large trial in the UK apparently reduced …
Dexamethasone in hospitalized patients with Covid-19
RECOVERY Collaborative Group - New England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) is associated with diffuse lung
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …
Dexamethasone in hospitalized patients with Covid-19-preliminary report
Background: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage.
Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce …
Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce …
Dexamethasone for the treatment of coronavirus disease (COVID-19): a review
MH Ahmed, A Hassan - SN comprehensive clinical medicine, 2020 - Springer
Abstract The World Health Organization (WHO) declared COVID-19 (novel coronavirus) as a
global pandemic in the middle of March 2020, after the disease spread to more than 150 …
global pandemic in the middle of March 2020, after the disease spread to more than 150 …
Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report
ABSTRACT Background Coronavirus disease 2019 (COVID-19) is associated with diffuse
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …
The use of dexamethasone in the treatment of COVID-19
M Lester, A Sahin, A Pasyar - Annals of Medicine and Surgery, 2020 - journals.lww.com
After reading around regarding the state of knowledge surrounding the COVID-19 outbreak,
we were intrigued by the lack of a general consensus on what constituted effective anti-viral …
we were intrigued by the lack of a general consensus on what constituted effective anti-viral …
[PDF][PDF] Short-term dexamethasone in Sars-CoV-2 patients
V Selvaraj, K Dapaah-Afriyie, A Finn, TP Flanigan - RI Med J, 2020 - rimed.org
ABSTRACT BACKGROUND: Dexamethasone, a synthetic glucocorticoid, has anti-
inflammatory and immunosuppressive properties. There is a hyperinflammatory response …
inflammatory and immunosuppressive properties. There is a hyperinflammatory response …
Coronavirus breakthrough: dexamethasone is first drug shown to save lives
H Ledford - 2020 - covid19.sld.cu
An inexpensive and commonly used steroid can save the lives of people seriously ill with
COVID-19, a randomized, controlled clinical trial in the United Kingdom has found. The drug …
COVID-19, a randomized, controlled clinical trial in the United Kingdom has found. The drug …
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
MA Matthay, BT Thompson - The Lancet Respiratory Medicine, 2020 - thelancet.com
The impressive results of the RECOVERY trial established that a moderate dose of
dexamethasone (6 mg daily for 10 days) reduced mortality in hospitalised patients with …
dexamethasone (6 mg daily for 10 days) reduced mortality in hospitalised patients with …
Potential adverse effects of dexamethasone therapy on COVID-19 patients: review and recommendations
F Chen, L Hao, S Zhu, X Yang, W Shi, K Zheng… - Infectious diseases and …, 2021 - Springer
In the context of the coronavirus disease 2019 (COVID-19) pandemic, the global healthcare
community has raced to find effective therapeutic agents against severe acute respiratory …
community has raced to find effective therapeutic agents against severe acute respiratory …